Sigyn Therapeutics, Inc. (SIGY)
USD 3.15
(0.0%)
USD 3.15
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.44 Million USD | -7.65% |
| 2022 | -2.13 Million USD | -10.84% |
| 2021 | -2.52 Million USD | -126.52% |
| 2020 | -905.13 Thousand USD | -104.49% |
| 2019 | -442.63 Thousand USD | 41.55% |
| 2018 | -1.7 Million USD | 65.55% |
| 2017 | -2.81 Million USD | -252.47% |
| 2016 | -549.42 Thousand USD | 72.3% |
| 2015 | -691.61 Thousand USD | -481.09% |
| 2014 | -387.54 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -628.45 Thousand USD | -6.59% |
| 2024 Q2 | -601.44 Thousand USD | 4.3% |
| 2023 Q2 | -571.39 Thousand USD | -10.17% |
| 2023 Q1 | -518.64 Thousand USD | 0.05% |
| 2023 FY | - USD | -7.65% |
| 2023 Q4 | -715.62 Thousand USD | -11.68% |
| 2023 Q3 | -640.79 Thousand USD | -12.15% |
| 2022 Q3 | -575.45 Thousand USD | -3.66% |
| 2022 Q4 | -518.91 Thousand USD | 9.83% |
| 2022 FY | - USD | -10.84% |
| 2022 Q1 | -623.15 Thousand USD | 45.39% |
| 2022 Q2 | -555.1 Thousand USD | 10.92% |
| 2021 FY | - USD | -126.52% |
| 2021 Q3 | -585.72 Thousand USD | -27.46% |
| 2021 Q1 | -400.12 Thousand USD | 41.66% |
| 2021 Q2 | -459.52 Thousand USD | -14.85% |
| 2021 Q4 | -1.14 Million USD | -94.8% |
| 2020 FY | - USD | -104.49% |
| 2020 Q1 | -80.63 Thousand USD | 25.33% |
| 2020 Q3 | -77.77 Thousand USD | -81.89% |
| 2020 Q2 | -42.76 Thousand USD | 46.97% |
| 2020 Q4 | -685.86 Thousand USD | -781.85% |
| 2019 Q2 | -81.96 Thousand USD | 45.11% |
| 2019 Q1 | -149.31 Thousand USD | -214.56% |
| 2019 FY | - USD | 41.55% |
| 2019 Q4 | -107.98 Thousand USD | -4.47% |
| 2019 Q3 | -103.36 Thousand USD | -26.12% |
| 2018 Q3 | -206.69 Thousand USD | 36.82% |
| 2018 Q4 | 130.33 Thousand USD | 163.06% |
| 2018 Q1 | -353.78 Thousand USD | 57.6% |
| 2018 Q2 | -327.14 Thousand USD | 7.53% |
| 2018 FY | - USD | 65.55% |
| 2017 Q2 | -556.85 Thousand USD | -92.79% |
| 2017 FY | - USD | -252.47% |
| 2017 Q4 | -834.38 Thousand USD | -60.0% |
| 2017 Q3 | -521.48 Thousand USD | 6.35% |
| 2017 Q1 | -288.83 Thousand USD | -129.41% |
| 2016 Q4 | 982.01 Thousand USD | 398.71% |
| 2016 Q3 | -328.75 Thousand USD | 37.52% |
| 2016 Q1 | -712.17 Thousand USD | 12.26% |
| 2016 Q2 | -526.19 Thousand USD | 26.11% |
| 2016 FY | - USD | 72.3% |
| 2015 Q1 | -151.51 Thousand USD | -7.68% |
| 2015 Q4 | -811.67 Thousand USD | 0.56% |
| 2015 FY | - USD | -481.09% |
| 2015 Q3 | -816.27 Thousand USD | -69.01% |
| 2015 Q2 | -482.97 Thousand USD | -218.77% |
| 2014 Q3 | -78.32 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | -140.7 Thousand USD | -79.63% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.556% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 58.737% |
| SQZ Biotechnologies Company | -64.14 Million USD | 96.186% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 85.916% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.602% |
| Mesoblast Limited | -62.38 Million USD | 96.079% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -59.27% |
| Genus plc | 73.7 Million USD | 103.319% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 62.997% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 31.027% |
| Marizyme, Inc. | -34.28 Million USD | 92.864% |
| ContraFect Corporation | -64.99 Million USD | 96.236% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 72.111% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 45.949% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -74.522% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 7.487% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -5.278% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -372.248% |
| Accustem Sciences Inc. | -3.74 Million USD | 34.699% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 94.927% |
| EV Biologics, Inc. | -1.26 Million USD | -93.071% |
| Q BioMed Inc. | -617.62 Thousand USD | -296.106% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 168.49% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -286.85% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -7.09% |
| Biomind Labs Inc. | -1.03 Million USD | -136.476% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 124.769% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 65.838% |
| Skye Bioscience, Inc. | -13.54 Million USD | 81.942% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -64.478% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -9685.844% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 37.017% |
| IMV Inc. | -35.52 Million USD | 93.113% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 84.584% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 2.218% |
| GB Sciences, Inc. | -1.41 Million USD | -72.3% |
| Alpha Cognition Inc. | -9.7 Million USD | 74.793% |
| HST Global, Inc. | -5303.00 USD | -46033.528% |
| CSL Limited | 4.78 Billion USD | 100.051% |
| Halberd Corporation | -74.27 Thousand USD | -3193.611% |
| Enzolytics Inc. | -2.12 Million USD | -15.289% |
| Resverlogix Corp. | -11.74 Million USD | 79.165% |
| Affymax, Inc. | -14.29 Million USD | 82.886% |
| SYBLEU INC | -141.57 Thousand USD | -1628.081% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 20.129% |
| argenx SE | -216.02 Million USD | 98.868% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.579% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 301.024% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -63.216% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 745.77% |
| AVAX Technologies, Inc. | -6.11 Million USD | 59.977% |
| Zenith Capital Corp. | -8.6 Million USD | 71.573% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.016% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -13943.172% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1289.842% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 93.828% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 15.415% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -133.818% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 36484.012% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -39.798% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -27.359% |
| BioStem Technologies, Inc. | -7.55 Million USD | 67.612% |
| ONE Bio Corp. | 13.61 Million USD | 117.971% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1250.979% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -18.933% |
| Agentix Corp. | -1.37 Million USD | -78.345% |
| LadRx Corporation | 412.28 Thousand USD | 693.394% |
| Cell Source, Inc. | -4.27 Million USD | 42.74% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -566.209% |
| Regen BioPharma, Inc. | 1.46 Million USD | 266.885% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -161.109% |
| NovAccess Global Inc. | -1.03 Million USD | -136.419% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 127.632% |
| Itoco Inc. | -1.86 Million USD | -30.897% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -544.45% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -119.217% |
| Kadimastem Ltd | -2.62 Million USD | 6.78% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -922.982% |
| CytoDyn Inc. | -18.02 Million USD | 86.43% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2995.65% |
| Mobile Lads Corp. | -2.24 Million USD | -9.161% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -19905.405% |
| Qrons Inc. | -40.08 Thousand USD | -6003.792% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -403.721% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 563.843% |
| Rebus Holdings, Inc. | -951 Thousand USD | -157.251% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -130.361% |
| International Stem Cell Corporation | 202 Thousand USD | 1311.119% |
| Bioxytran, Inc. | -3.82 Million USD | 35.959% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4547.532% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 0.628% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 93.179% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5336.58% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 10.648% |
| Neutra Corp. | -181.24 Thousand USD | -1249.794% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 87.864% |
| PureTech Health plc | -11.62 Million USD | 78.959% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 87.863% |
| IXICO plc | -707 Thousand USD | -246.034% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 68.166% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 94.94% |
| CSL Limited | 4.73 Billion USD | 100.052% |
| Cellectis S.A. | -92.63 Million USD | 97.359% |